论文部分内容阅读
尿激酶受体 (u PAR)是由体内多种细胞表达的单链膜糖蛋白 ,介导尿激酶催化的纤溶酶原活化与纤溶过程 ,并参与基质的水解、信号传递和细胞的粘附 ,在肿瘤侵润和转移、炎症与血栓形成中具有重要作用。u PAR的检测可作为肿瘤预后及炎症、阵发性睡眠性血红蛋白尿等多种疾病状态的判断指标 ,调节u PAR的表达与功能可能成为肿瘤、炎症以及动脉粥样硬化治疗的一个新的途径。
Urokinase receptor (uPAR), a single-chain membrane glycoprotein expressed by many cells in the body, mediates urokinase-catalyzed plasminogen activation and fibrinolytic processes and is involved in the hydrolysis, signaling and cell adhesion of the matrix Attached, plays an important role in tumor invasion and metastasis, inflammation and thrombosis. u PAR detection can be used as a prognostic indicator of tumor prognosis and inflammation, paroxysmal nocturnal hemoglobinuria and other diseases, and regulation of u PAR expression and function may become a new approach for the treatment of tumors, inflammation and atherosclerosis .